Which patients without CAD or equivalents should be on a statin?
Metadata[+] Show full item record
In patients without cardiovascular disease (CVD), HMG CoA reductase inhibitor (statin) use safely reduces the 5-year incidence of major coronary events by 29.2%, coronary revascularization by 33.8%, nonfatal myocardial infarction (MI) by 31.7%, and stroke by 14.4%, but with no statistically significant reduction in all-cause mortality (SOR: A, based on an RCT/systematic review). For patients at moderately high risk for CVD, statin therapy is cost effective and reduces major coronary events and CVD (SOR: A, based on an RCT). For patients at low risk, statin therapy is not cost effective.
Evidence Based Practice 13(10): 04-05.